Clinical trial
A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to…
NCT00420992 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00420992 |
|---|---|
| Title | A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Efficacy Study of Kadian NT (Morphine Sulfate Plus Naltrexone Hydrochloride Extended-Release) Capsules in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Hip or Knee |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoarthritis, Chronic Pain |
| Intervention type | Drug |
| Interventions | ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release), Placebo |
| Enrollment | 547 |
| Start date | Dec 1, 2006 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Jan 11, 2007 |
| Last update posted | Sep 20, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: